Abcellera Biologics Inc (ABCL)

$3.82 +0.21 (5.82%)
Market Cap 1.09B
Revenue (ttm) 28.83M
Net Income (ttm) -162.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.90%
Debt to Equity Ratio 0.00
Volume 5,092,300
Avg Vol 4,425,882
Day's Range N/A - N/A
Shares Out 303.16M
Stochastic %K 98%
Beta 0.81
Analysts Strong Sell
Price Target $8.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 West 4th Ave, Vancouver, Canada
_DragonForce1
_DragonForce1 Mar. 3 at 2:10 AM
^ @SqueezeSharkie has clearly set the pace this year. ^Stay informed and up to date by following, doesn't cost you anything but a click!! $ABCL $CPIX $IRD $ANGX <<<< watching
0 · Reply
50bps
50bps Mar. 2 at 10:51 PM
$ABCL bazinga
0 · Reply
TheinvestmetABCD
TheinvestmetABCD Mar. 2 at 10:24 PM
$ABCL First major resistance $4,20. If we take that out and backtest succesfully $6 coming
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Mar. 2 at 9:44 PM
$ABCL back to 8
0 · Reply
snowPOW
snowPOW Mar. 2 at 9:37 PM
$ABCL nice
0 · Reply
DeMampCamp
DeMampCamp Mar. 2 at 8:58 PM
$ABCL
0 · Reply
UncleTomFlorida
UncleTomFlorida Mar. 2 at 8:23 PM
$ABCL Carl & Co acquires 38,000 shares. https://d18rn0p25nwr6d.cloudfront.net/CIK-0001703057/8f539868-1b1e-44a5-a53d-a2fdfc27c65c.pdf
1 · Reply
estatebuyersmia
estatebuyersmia Mar. 2 at 7:18 PM
$ABCL
1 · Reply
DragonAlgo
DragonAlgo Mar. 2 at 5:54 PM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $3.00 | Type: CALL Option Plan (premium): Entry: $0.82 Stop: $0.59 TP1: $1.07 TP2: $1.40 TP3: $1.98 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
Kaykay610
Kaykay610 Mar. 2 at 4:55 PM
$ABCL https://investors.rallybio.com/news-releases/news-release-details/rallybio-corporation-and-candid-therapeutics-announce-merger/
1 · Reply
Latest News on ABCL
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 7:27 PM EST - 6 days ago

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 6 days ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 19 days ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 5 weeks ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 9:16 PM EST - 6 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 7 weeks ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 2 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 3 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 8, 2025, 1:37 PM EST - 3 months ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 12:23 AM EST - 3 months ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 4 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 7:16 PM EST - 4 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 4 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera Biologics: Entering Growth Phase After A Pause

Oct 6, 2025, 7:35 AM EDT - 5 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 6 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 6 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:48 PM EDT - 7 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 7 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 9 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 10 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 10 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 10 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 10 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 10 months ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 10 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

_DragonForce1
_DragonForce1 Mar. 3 at 2:10 AM
^ @SqueezeSharkie has clearly set the pace this year. ^Stay informed and up to date by following, doesn't cost you anything but a click!! $ABCL $CPIX $IRD $ANGX <<<< watching
0 · Reply
50bps
50bps Mar. 2 at 10:51 PM
$ABCL bazinga
0 · Reply
TheinvestmetABCD
TheinvestmetABCD Mar. 2 at 10:24 PM
$ABCL First major resistance $4,20. If we take that out and backtest succesfully $6 coming
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Mar. 2 at 9:44 PM
$ABCL back to 8
0 · Reply
snowPOW
snowPOW Mar. 2 at 9:37 PM
$ABCL nice
0 · Reply
DeMampCamp
DeMampCamp Mar. 2 at 8:58 PM
$ABCL
0 · Reply
UncleTomFlorida
UncleTomFlorida Mar. 2 at 8:23 PM
$ABCL Carl & Co acquires 38,000 shares. https://d18rn0p25nwr6d.cloudfront.net/CIK-0001703057/8f539868-1b1e-44a5-a53d-a2fdfc27c65c.pdf
1 · Reply
estatebuyersmia
estatebuyersmia Mar. 2 at 7:18 PM
$ABCL
1 · Reply
DragonAlgo
DragonAlgo Mar. 2 at 5:54 PM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $3.00 | Type: CALL Option Plan (premium): Entry: $0.82 Stop: $0.59 TP1: $1.07 TP2: $1.40 TP3: $1.98 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
Kaykay610
Kaykay610 Mar. 2 at 4:55 PM
$ABCL https://investors.rallybio.com/news-releases/news-release-details/rallybio-corporation-and-candid-therapeutics-announce-merger/
1 · Reply
Ed_Ng
Ed_Ng Mar. 2 at 4:33 PM
$ABCL garbage 🗑️
0 · Reply
Ckkung71
Ckkung71 Mar. 2 at 4:04 PM
$ABCL Insider baying… shorters (20%) must be a little bit sweaty..
0 · Reply
EchoAnalysis8
EchoAnalysis8 Mar. 2 at 10:13 AM
$ABCL — about to break out We’ve charted the bottom perfectly. I’m buying once price flips both moving averages to support. Wave 5 target → +246%
0 · Reply
JennyRowes
JennyRowes Mar. 1 at 6:52 PM
$GENB watching this one alongside $RXRX, $ABSI and $ABCL
0 · Reply
UgoGreg
UgoGreg Feb. 28 at 9:49 PM
$ABCL https://youtu.be/ygBN8MilTyc
0 · Reply
raccoonblackbear
raccoonblackbear Feb. 28 at 4:22 PM
$ABCL just when things were looking to break $4... war announcement. Let's see how the market fares on Monday.
2 · Reply
JennyRowes
JennyRowes Feb. 28 at 3:34 PM
$ABCL is this correct? > $ 20M purchased and no sales in the last 5 years?? https://www.secform4.com/insider-trading/1703057.htm
1 · Reply
Kaykay610
Kaykay610 Feb. 28 at 1:49 PM
$ABCL we are just building in silence!!
1 · Reply
hichemben
hichemben Feb. 28 at 8:56 AM
$ABCL Andrew Booth (CFO) made an "open-market" purchase yesterday, Thermopylae Holdings Ltd. is a 10% owner and a primary investment vehicle for AbCellera’s founder and CEO, Carl Hansen. Super #Bullish signal for a solid reversal🚀
0 · Reply
snowPOW
snowPOW Feb. 28 at 2:40 AM
$ABCL great news! Insider Buying
0 · Reply
sogenerous
sogenerous Feb. 28 at 2:01 AM
$ABCL nice insider buys by CEO 177k and 42k CFO. I am holding 1/3 my at the bottom purchae from 2025 still
0 · Reply
tkstockpicker
tkstockpicker Feb. 28 at 12:44 AM
$ABCL Should now be support.
1 · Reply